Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

CSL Ltd

Healthcare US CSLLY

17.12USD
0.49(2.95%)

Last update at 2026-06-05T19:50:00Z

Day Range

17.0017.31
LowHigh

52 Week Range

22.8343.77
LowHigh

Fundamentals

  • Previous Close 16.63
  • Market Cap47988.33M
  • Volume31296
  • P/E Ratio16.05
  • Dividend Yield2.93%
  • EBITDA4840.00M
  • Revenue TTM15407.00M
  • Revenue Per Share TTM7.96
  • Gross Profit TTM 7992.00M
  • Diluted EPS TTM1.54

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax 3724.00M 3375.00M 2663.00M 2779.60M 2963.10M
Minority interest -134.00000M -72.00000M -50.00000M - -
Net income 3002.00M 2642.00M 2194.00M 2254.70M 2375.00M
Selling general administrative 1000.00M 856.00M 1086.00M 688.00M 731.70M
Selling and marketing expenses 1616.00M 1573.00M 1454.00M 960.70M 980.20M
Gross profit 7951.00M 7561.00M 6708.00M 5663.50M 5798.60M
Reconciled depreciation 1017.00M 938.00M 831.00M 542.50M 495.30M
Ebit 4117.00M 3795.00M 3071.00M 2922.40M 3198.18M
Ebitda 5134.00M 4733.00M 3902.00M 3464.90M 3629.20M
Depreciation and amortization 1017.00M 938.00M 831.00M 542.50M 431.02M
Non operating income net other - - - - -
Operating income 2959.00M 3812.00M 4884.05M 4239.47M 4174.17M
Other operating expenses 12471.00M 11926.00M 3989.22M 2951.84M 2322.20M
Interest expense 454.88M 484.22M 408.00M 142.80M 170.80M
Tax provision 588.00M 661.00M 419.00M 524.90M 588.10M
Interest income 38.00M 39.00M 38.00M 17.40M 3.90M
Net interest income -410.00000M -437.00000M -406.00000M -160.60000M -166.90000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 588.00M 661.00M 419.00M 524.90M 588.10M
Total revenue 15430.00M 14800.00M 13174.00M 10493.10M 10265.30M
Total operating expenses 4992.00M 4797.00M 4606.00M 3347.40M 3208.60M
Cost of revenue 7479.00M 7129.00M 6466.00M 4829.60M 4466.70M
Total other income expense net 765.00M -437.00000M 136.00M 81.60M 44.70M
Discontinued operations - - - - -
Net income from continuing ops 3136.00M 2714.00M 2244.00M 2254.70M 2375.00M
Net income applicable to common shares - - 2194.00M 2254.70M 2375.00M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 39404.00M 38022.00M 36234.00M 28346.00M 18156.90M
Intangible assets 8120.00M 8267.00M 8367.00M 1450.80M 1481.60M
Earning assets - - - - -
Other current assets 345.00M 506.00M 9.00M 4.20M 231.80M
Total liab 17997.00M 18621.00M 18408.00M 13768.50M 9775.60M
Total stockholder equity 19335.00M 17363.00M 15786.00M 14577.50M 8381.30M
Deferred long term liab - - - - -
Other current liab 3203.00M 2963.33M 5687.30M 9437.77M 49.70M
Common stock 574.00M 5062.00M 517.00M 483.80M 483.80M
Capital stock 574.00M 557.00M 517.00M 483.80M -4504.60000M
Retained earnings 17744.00M 16012.00M 14621.00M 13503.40M 12252.70M
Other liab - - 2628.00M 1496.50M 1338.90M
Good will 8065.00M 8079.00M 8079.00M 1187.30M 1188.10M
Other assets - - 1177.00M 938.60M 561.50M
Cash 2157.00M 1657.00M 1548.00M 10436.40M 1808.80M
Cash and equivalents - - - - -
Total current liabilities 4815.00M 4950.00M 4608.00M 7108.20M 3103.60M
Current deferred revenue - 3129.00M -2954.30320M -7415.37440M 2057.10M
Net debt 9341.00M 10526.00M 10679.00M -778.60000M 3998.10M
Short term debt 804.00M 944.00M 1055.00M 4494.00M 473.80M
Short long term debt 695.00M 848.00M 964.00M 4420.50M 396.00M
Short long term debt total 11498.00M 12183.00M 12227.00M 9657.80M 5806.90M
Other stockholder equity - -4505.00000M -29492.00020M -26783.81280M -16340.20072M
Property plant equipment - - 9352.00M 8308.60M 7536.00M
Total current assets 11850.00M 10768.00M 9259.00M 16460.70M 7389.70M
Long term investments 203.00M 163.00M 173.00M 402.90M 21.50M
Net tangible assets - - -660.00000M 11939.40M 5711.60M
Short term investments - 157.48M - - 4.80M
Net receivables 2882.00M 2641.00M 1905.00M 1483.20M 1563.70M
Long term debt 9141.00M 9671.00M 9564.00M 3862.50M 4228.50M
Inventory 6466.00M 5964.00M 5466.00M 4333.00M 3780.60M
Accounts payable 808.00M 867.00M 820.00M 591.80M 523.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 1017.00M 794.00M 648.00M 590.30M 633.20M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 278.00M 177.71M 102.00M 18.20M 10.50M
Deferred long term asset charges - - - - -
Non current assets total 27554.00M 27254.00M 26975.00M 11885.30M 10767.20M
Capital lease obligations 1662.00M 1664.00M 1699.00M 1374.80M 1182.40M
Long term debt total - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments -850.00000M -1259.00000M -11843.00000M -387.70000M -387.70000M
Change to liabilities - - 197.00M 212.30M 454.90M
Total cashflows from investing activities -850.00000M -1259.00000M -11843.00000M -1636.10000M -1673.20000M
Net borrowings -735.00000M 41.00M 1661.00M 3723.70M -496.70000M
Total cash from financing activities -2241.00000M -1284.00000M 456.00M 7675.90M -1401.80000M
Change to operating activities - - 51.00M -102.70000M 56.40M
Net income 3002.00M 2687.61M 3294.07M 3266.14M 3167.30M
Change in cash 514.00M 134.00M -8825.00000M 8604.30M 578.80M
Begin period cash flow 1643.00M 1509.00M 10334.00M 1730.10M 1151.30M
End period cash flow 2157.00M 1643.00M 1509.00M 10334.40M 1730.10M
Total cash from operating activities 3561.00M 2764.00M 3905.14M 3807.84M 4830.17M
Issuance of capital stock 17.00M 40.00M 34.00M 4988.40M 56.40M
Depreciation - 954.19M 1088.52M 647.43M 533.84M
Other cashflows from investing activities -381.00000M -410.00000M - -0.70000M -6.10000M
Dividends paid 1434.00M 1212.58M -1239.00000M -1038.70000M -958.00000M
Change to inventory -637.64744M -780.00000M -1361.76980M -1306.45680M -490.36472M
Change to account receivables -318.82372M -766.00000M 42.04M -65.17800M 48.68M
Sale purchase of stock - - 2539.00M 4092.70M 38.70M
Other cashflows from financing activities -89.00000M -152.42275M -80.00000M -50.10000M -68.00000M
Change to netincome - - 207.00M 668.80M 571.50M
Capital expenditures 1017.00M 1258.00M 1692.00M 1247.70M 1667.10M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -878.28827M -1587.00000M -1319.73060M -1371.63480M -441.68832M
Stock based compensation - 169.00M 208.69M 169.46M 122.42M
Other non cash items 4439.29M 709.20M -477.44520M -105.73320M 1129.03M
Free cash flow 2544.00M 1506.00M 2213.14M 2560.14M 3163.07M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CSLLY
CSL Ltd		 0.49 2.95% 17.12 16.05 18.80 3.11 2.58 3.71 11.15
NVO
Novo Nordisk A/S		 -0.79 1.81% 42.96 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.6937 1.57% 43.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.09 1.15% 446.83 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.72 1.07% 635.45 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. This segment also offers therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. It also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

CSL Ltd

655 Elizabeth Street, Melbourne, VIC, Australia, 3000

Key Executives

Name Title Year Born
Mr. Paul R. Perreault B.A. MD, CEO & Exec. Director 1957
Ms. Joy Carolyn Linton B.Com., BComm, GAICD, Grad Dip AFI Chief Financial Officer 1965
Dr. Paul F. McKenzie Ph.D. Chief Operating Officer 1966
Mr. Mark Dehring Head of Investor Relations NA
Mr. Gregory Boss B.S., BS(Hons), J.D. Exec. VP of Legal & Group Gen. Counsel 1961
Christina Hickie Sr. Mang. of Communications NA
Ms. Elizabeth Walker B.A., M.S. Exec. VP & Chief HR Officer 1970
Dr. Karen Etchberger Exec. VP of Quality & Bus. Services 1958
Dr. Wilfried Freudenberg Department Head of Albumin & Immunoglobulins Production NA
Ms. Jemimah Brennan Head of Communications - Asia Pacific NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.